Clinical Trials Logo

Clinical Trial Summary

The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis [JoAS]) and juvenile psoriatic arthritis (JPsA).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04527380
Study type Interventional
Source Eli Lilly and Company
Contact
Status Active, not recruiting
Phase Phase 3
Start date April 13, 2021
Completion date April 24, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Completed NCT05252533 - A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis Phase 1
Completed NCT03031782 - Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) Phase 3
Recruiting NCT05767047 - A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis Phase 3
Active, not recruiting NCT03769168 - An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) Phase 3
Recruiting NCT06100744 - A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab Phase 3